THBS2 and hepatocellular carcinoma: HCC history (hazard ratio [HR] 9.05, 95% confidence interval [CI] 3.36–24.38, p < 0.001), cirrhosis (HR 4.48, 95% CI 1.68–11.93, p = 0.003), Plt Low at SVR12 < 11.75 (HR 3.70, 95% CI 1.39–9.87, p = 0.009), FIB‐4 High at SVR12 ≥ 3.538 (HR 5.04, 95% CI 1.83–13.87, p = 0.002), APRI High at SVR12 ≥ 0.692 (HR 4.06, 95% CI 1.48–11.18, p = 0.007) and TSP2 High at SVR12 ≥ 32.12 (HR 3.96, 95% CI 1.47–10.64, p = 0.006) were all significantly associated with HCC occurrence after DAA treatment.